FORM 8-K
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, DC 20549
CURRENT REPORT
Pursuant to Section 13 or 15(d) of
the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): April 15, 2004
DUSA PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
NEW JERSEY 0-19777 22-3103129
(State or other (Commission (IRS Employer
jurisdiction of File Number) Identification
incorporation) Number)
25 UPTON DRIVE
WILMINGTON, MASSACHUSETTS 01887
(Address of principal executive offices, including ZIP code)
(978) 657-7500
(Registrant's telephone number, including area code)
ITEM 5. OTHER EVENTS.
On April 15, 2004, DUSA Pharmaceuticals, Inc. announced that on April 14, 2004
it received exercise notices from all investors in its recently completed
private placement relating to the exercise of additional investment rights to
purchase 337,500 shares of its common stock at a price of $11.00 per share.
ITEM 7. FINANCIAL STATEMENTS AND OTHER EXHIBITS.
[99] Press Release dated April 15, 2004.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the
Registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
DUSA PHARMACEUTICALS, INC.
Dated: April 15, 2004 By: /s/ D. Geoffrey Shulman
---------------------------------------
D. Geoffrey Shulman, MD, FRCPC
President and Chief Executive Officer